JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 17, 2004; DOI: 10.1124/jpet.104.078105


0022-3565/05/3131-70-77$20.00
JPET 313:70-77, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.078105v1
313/1/70    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ergul, A.
Right arrow Articles by Anstadt, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ergul, A.
Right arrow Articles by Anstadt, M. P.

CARDIOVASCULAR

Vascular Dysfunction of Venous Bypass Conduits Is Mediated by Reactive Oxygen Species in Diabetes: Role of Endothelin-1

Adviye Ergul, Jeanette Schultz Johansen, Catherine Strømhaug, Alex K. Harris, Jimmie Hutchinson, Amany Tawfik, Ali Rahimi, Edward Rhim, Bryan Wells, R. William Caldwell, and Mark P. Anstadt

Clinical and Experimental Therapeutics Program, University of Georgia College of Pharmacy (A.E., A.K.H., J.H.), Vascular Biology Center (A.E., A.T., M.P.A.), Departments of Surgery (A.R., E.R., B.W., M.P.A.) and Pharmacology and Toxicology (R.W.C.), Medical College of Georgia, Augusta, Georgia; and University of Tromsø Institute of Pharmacy, Tromsø, Norway (J.S.J., C.S.)

Diabetes is associated with increased risk for complications following coronary bypass grafting (CABG) surgery. Augmented superoxide production plays an important role in diabetic complications by causing vascular dysfunction. The potent vasoconstrictor endothelin-1 (ET-1) is also elevated in diabetes and following CABG; however, the effect of ET-1 on generation and/or vascular dysfunction in bypass conduits remain unknown. Accordingly, this study investigated basal and ET-1-stimulated production in bypass conduits and determined the effect of on conduit reactivity. Saphenous vein specimens were obtained from nondiabetic (n = 24) and diabetic (n = 24) patients undergoing CABG. Dihydroethidium staining and NAD(P)H oxidase activity assays (5380 ± 940 versus 16,362 ± 2550 relative light units/µg) demonstrated increased basal levels in the diabetes group (p < 0.05). Plasma ET-1 levels were associated with elevated basal levels, and treatment of conduits with exogenous ET-1 further increased production and augmented vasoconstriction. Furthermore, vascular relaxation was impaired in the diabetic group (75 versus 40%), which was restored by scavenger superoxide dismutase. These findings suggest that ET-1 causes bypass conduits dysfunction via stimulation of production in diabetes. Novel therapies that attenuate generation in bypass conduits may improve acute and late outcome of CABG in diabetic patients.


Received September 17, 2004; accepted December 6, 2004.

Address correspondence to: Dr. Adviye Ergul, Medical College of Georgia, Clinical Pharmacy CJ-1020, 1120 15th Street, Augusta, GA 30912. E-mail: aergul{at}mail.mcg.edu




This article has been cited by other articles:


Home page
VASC ENDOVASCULAR SURGHome page
K. G. Maier
Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Diabetes: Vascular Implications
Vascular and Endovascular Surgery, August 1, 2008; 42(4): 305 - 313.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
F. Bohm and J. Pernow
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
Cardiovasc Res, October 1, 2007; 76(1): 8 - 18.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
K. Sachidanandam, A. Harris, J. Hutchinson, and A. Ergul
Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1016 - 1021.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
I. G. Obrosova, V. R. Drel, P. Pacher, O. Ilnytska, Z. Q. Wang, M. J. Stevens, and M. A. Yorek
Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited
Diabetes, December 1, 2005; 54(12): 3435 - 3441.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.